Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC)

被引：0
|
作者：
Hamilton, Erika P.
Jauhari, Shekeab
Moore, Kathleen N.
Rini, Brian I.
McLeod, Robert
Lin, Jie
Izumi, Nanae
Kundu, Madan Gopal
Myobatake, Yusuke
Laadem, Abderrahmane
Noguchi, Yutaka
Kirui, Julius
Spigel, David R.
机构：
[1] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[2] Sarah Cannon Res Inst, Florida Canc Specialists, Lake Mary, FL USA
[3] Univ Oklahoma, HSC, Sarah Cannon Res Inst, Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[6] Daiichi Sankyo, Basking Ridge, NJ USA
[7] Daiichi Sankyo Co Ltd, Tokyo, Japan
[8] Sarah Cannon Dev Innovat, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3002
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors.
    Bendell, Johanna C.
    Doi, Toshihiko
    Patel, Manish R.
    Piha-Paul, Sarina Anne
    Sen, Shiraj
    Shimizu, Toshio
    Cheng, Ben
    Mekan, Sabeen F.
    Myobatake, Yusuke
    Okuda, Yasuyuki
    Serbest, Gul
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
    Konecny, G. E.
    Hendrickson, A. E. Wahner
    Winterhoff, B.
    Adjei, A. A.
    Kung, A.
    Miller, L-L.
    Press, M. F.
    Qazi, I.
    Scholler, N.
    Dokainish, H.
    Letrent, S.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S551 - S551
  • [3] Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study
    Moore, K. N.
    Philipovskiy, A.
    Harano, K.
    Rini, B. I.
    Sudo, K.
    Kitano, S.
    Spigel, D. R.
    Lin, J.
    Kundu, M.
    Bensmaine, A.
    Myobatake, Y.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S510 - S510
  • [4] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
    Koganemaru, S.
    Yoshizuka, N.
    Mizuno, S.
    Hirai, S.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
  • [5] Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1-23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors
    Konecny, Gottfried
    Hendrickson, Andrea Wahner
    Winterhoff, Boris
    Kung, Adrine
    Miller, Lei-Lani
    Press, Michael
    Qazi, Ibrahim
    Scholler, Nathalie
    Dokainish, Hatem
    Letrent, Stephen
    Slamon, Dennis
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A56 - A56
  • [6] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Chen, Yu-ling
    Jia, Ru
    Shen, Lin
    Wang, Jian
    Sai, Yang
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
    Tao, Jessica J.
    Cangemi, Nicholas A.
    Makker, Vicky
    Cadoo, Karen A.
    Liu, Joyce F.
    Rasco, Drew W.
    Navarro, Willis H.
    Haqq, Christopher M.
    Hyman, David M.
    CLINICAL CANCER RESEARCH, 2019, 25 (18) : 5458 - 5465
  • [8] A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
    George, Suzanne
    Heinrich, Michael C.
    Somaiah, Neeta
    Oppelt, Peter
    McLeod, Robert
    Nishioka, Satoshi
    Kundu, Madan G.
    Qian, Xiaozhong
    Kumar, Prasanna
    Laadem, Abderrahmane
    Lau, Yvonne
    Tran, Brittany P.
    Fallon, Maura
    Dosunmu, Ololade
    Shi, Julia
    Naito, Yoichi
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3659 - 3667
  • [9] A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors
    Johnson, M. L.
    Doi, T.
    Piha-Paul, S. A.
    Sen, S.
    Shimizu, T.
    Cheng, B.
    Yoshizuka, N.
    Okamoto, N.
    Okuda, Y.
    Qian, X.
    Serbest, G.
    Hammett, T.
    Brady, W. E.
    Patel, M. R.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S583 - S585
  • [10] A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
    Cavalcante, L.
    Siu, L. L.
    Toso, J.
    Mires, D.
    Shiga, R.
    Maruca, J.
    Ayele, G.
    Vuppala, P. Kumar
    Cheng, Y.
    Huang, L.
    Connolly, J. E.
    Ishimoto, Y.
    Sue, M.
    Bedard, P. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S333 - S333
12345